Financial Data and Key Metrics Changes - The company achieved record revenue of $18.9 million, representing a robust 16.3% year-over-year growth compared to $16.3 million in the same period last year [4][13] - Operating income increased to $3.6 million, reflecting a growth rate of 42.4% year-over-year, with operating income as a percentage of sales reaching 19% [5][14] - Net income rose by 40.3% to $2.8 million, or $0.32 per diluted share, compared to $2 million, or $0.22 per diluted share in the previous year [15] Business Line Data and Key Metrics Changes - Revenue in the direct home care business increased by 18.4% to $17.3 million, driven by an increase in direct sales representatives and higher net revenues per representative [13] - Home care distributor revenue grew 12.1%, totaling $0.9 million for the quarter [14] - Hospital revenue decreased by 9.4% to $0.7 million due to strategic prioritization of shipments to home patients [5][14] Market Data and Key Metrics Changes - The company executed 25 payer contracts in the first half of the fiscal year, adding 2.9 million covered lives to the existing 270 million [9] - Approximately 923,000 patients in the U.S. are diagnosed with bronchiectasis, with only 16% currently benefiting from high-frequency chest wall oscillation therapy, indicating a significant market opportunity [7] Company Strategy and Development Direction - The primary strategic opportunity lies in addressing the underserved bronchiectasis market, with a focus on raising awareness and education [7] - The company launched the "Triple Down on Bronchiectasis" campaign, promoting a three-pronged treatment approach [8] - The company is enhancing its sales organization, planning to increase the number of direct sales representatives from 58 to 61 by the end of the fiscal year [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, highlighting the 13th consecutive quarter of revenue and profit growth [4][42] - The company remains vigilant about potential challenges related to tariffs affecting domestic suppliers but believes its U.S.-centric operations provide a competitive advantage [11] - Management anticipates a rebound in hospital demand in the coming quarters [5] Other Important Information - The company has a strong balance sheet with $13.8 million in cash and no debt, reflecting a commitment to shareholder value through a $10 million stock repurchase authorization [6][15] - The implementation of the Smart Order ePrescribe solution is improving order fulfillment efficiency, with over one-third of orders received through this platform [10] Q&A Session Summary Question: Home care Medicare segment performance - Management noted strong execution of their strategy and increased awareness of bronchiectasis among prescribing physicians [18][19] Question: Impact of Brinsupri on business - Management indicated that Brinsupri serves as an adjunct to airway clearance, enhancing awareness of bronchiectasis and complementing the SmartVest technology [20][21] Question: Rep productivity and future trends - Management expects productivity per rep to remain within the $1 million-$1.1 million range, considering the training period for new hires [25][26] Question: Growth among government vs. commercial payers - Management highlighted that there are no significant trends favoring one payer type over the other, with a focus on driving referrals [33][34] Question: Share buyback strategy - Management stated that the board continuously monitors cash position and share pricing to optimize repurchase timing [36][38]